Literature DB >> 31100539

Downregulation of Cdc6 inhibits tumorigenesis of osteosarcoma in vivo and in vitro.

Wei Jiang1, Yun Yu2, Juan Liu3, Qiuyan Zhao4, Juan Wang5, Jing Zhang6, Xiaoqian Dang7.   

Abstract

BACKGROUND: Osteosarcoma is the most frequent malignant bone cancer in teenagers. In this study, cell division cycle 6 (Cdc6) was upregulated in the tumor tissues from patients with osteosarcoma according to the results of RNA sequencing. Cdc6 has been considered as a candidate prognostic marker, which was associated with cell apoptosis and cell cycle. However, the mechanisms by which Cdc6 regulates the apoptosis and cell cycle arrest in osteosarcoma remain unclear.
METHODS: Firstly, 3 pairs of osteosarcoma and adjacent normal tissues were subjected to RNA sequencing. In addition, the levels of Cdc6 in 30 pairs of patients' tissues and in osteosarcoma cell lines were detected by western blotting and RT-qPCR. Moreover, the effects of Cdc6 on cell proliferation, apoptosis, cell cycle and invasion were evaluated by cell counting kit-8 (CCK-8), flow cytometric and transwell assay, respectively.
RESULTS: Cdc6 was significantly upregulated in patients with osteosarcoma and in osteosarcoma cell lines. Downregulation of Cdc6 inhibited the proliferation and invasion of MG63 cells by promoting apoptosis. In addition, downregulation of Cdc6 induced G1 phase cell cycle arrest. Moreover, inhibition of Cdc6 downregulated the expression of Cyclin D1 and Cyclin A2, and upregulated the level of p21 in MG63 cells. In vivo study confirmed downregulation of Cdc6 inhibited osteosarcoma tumor growth by inducing apoptosis.
CONCLUSION: Our findings indicated that Cdc6 may serve as an oncogene in osteosarcoma. Thus, inhibiting Cdc6 may be a therapeutic approach for the treatment of osteosarcoma.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cell cycle arrest; Cell division cycle 6; Invasion; Osteosarcoma

Mesh:

Substances:

Year:  2019        PMID: 31100539     DOI: 10.1016/j.biopha.2019.108949

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.

Authors:  H Zhao; X Zhou; G Yuan; Z Hou; H Sun; N Zhai; B Huang; X Li
Journal:  Clin Transl Oncol       Date:  2020-07-13       Impact factor: 3.405

2.  Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling pathway.

Authors:  Xin Zhao; Yuying Fang; Xingwen Wang; Zhouyuan Yang; Donghai Li; Meng Tian; Pengde Kang
Journal:  Int J Oncol       Date:  2019-11-14       Impact factor: 5.650

3.  Potential Prognostic and Diagnostic Values of CDC6, CDC45, ORC6 and SNHG7 in Colorectal Cancer.

Authors:  Yang Hu; Liping Wang; Zhixing Li; Zirui Wan; Mingjie Shao; Shaobin Wu; Guo Wang
Journal:  Onco Targets Ther       Date:  2019-12-31       Impact factor: 4.147

4.  Identification of Ten Core Hub Genes as Potential Biomarkers and Treatment Target for Hepatoblastoma.

Authors:  Rui Sun; Simin Li; Ke Zhao; Mei Diao; Long Li
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

5.  The biological function and clinical significance of STIL in osteosarcoma.

Authors:  Shu-Fan Ji; Sheng-Lian Wen; Yu Sun; Pi-Wei Huang; Hao Wu; Mao-Lin He
Journal:  Cancer Cell Int       Date:  2021-04-15       Impact factor: 5.722

6.  Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells.

Authors:  Yuna Youn; Jong-Chan Lee; Jaihwan Kim; Jae Hyeong Kim; Jin-Hyeok Hwang
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.